Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Gino Perri"'
Autor:
Marco, Maruzzo, Francesco, Pierantoni, Alberto, Bortolami, Dario, Palleschi, Andrea, Zivi, Maurizio, Nicodemo, Donata, Sartori, Rocco, De Vivo, Fable, Zustovich, Davide, Bimbatti, Davide, Pastorelli, Giuseppe Dione, Vultaggio, Mariella, Soraru', Melissa, Ballestrin, Caterina, Modonesi, Paola, Randisi, Carmen, Barile, Gino, Perri, Umberto, Basso, Vittorina, Zagonel
Publikováno v:
Targeted oncology. 17(4)
Second- or third-line treatment options for metastatic renal cell carcinoma (mRCC) have dramatically changed in the last few years. There are no criteria for the choice between nivolumab and cabozantinib, which both demonstrated overall survival (OS)
Autor:
Laura Cosmai, Maria Giuseppa Vitale, Cinzia Baldessari, Stefania Di Girolamo, Michele Milella, Roberto Sabbatini, Krisida Cerma, Camillo Porta, Stefania Pipitone, Marco Maruzzo, Umberto Basso, Sebastiano Buti, Gino Perri, Anna Maria Militello, Giuseppe Fornarini, Stefano Cascinu
Background In the last few years, several new drugs such targeted therapy and immunotherapy have shown activity and have been approved for the treatment of metastatic renal cell carcinoma (mRCC). In mRCC, nivolumab, anti-PD-1 antibody, has recently b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3875e8e404c3dc20b122c8c1df5c47b1
Autor:
Andrea Zivi, Carmen Barile, Umberto Basso, Davide Pastorelli, Vittorina Zagonel, Giulia Zanchetta, Donata Sartori, Davide Bimbatti, Caterina Modonesi, Paola Randisi, Gino Perri, Rocco De Vivo, Dario Palleschi, G. Vultaggio, Fable Zustovich, Alberto Bortolami, Marco Maruzzo, Melissa Ballestrin, Mariella Sorarù, Maurizio Nicodemo
Publikováno v:
Journal of Clinical Oncology. 39:290-290
290 Background: Second (2L) or third-line (3L) treatment options for mRCC have dramatically changed in the last years. The standard of care as per Italian Regulatory Agencies approvals is N or C. To date, there are no criteria for the choice between
Autor:
Laura Paletta, Gino Perri, Christian Leporini, Francesca Saullo, Antonio Sorrentino, Gianluca Dima, Gaetana La Gattuta, Virginia Olivito, Giovambattista De Sarro, Rosa Toscano, Stefania Infusino, Gianfranco Filippelli, Maria Lucia, Ugo Bottoni
Publikováno v:
Journal of Pharmacology & Pharmacotherapeutics
Introduction: The epidermal growth factor receptor inhibitors (EGFRIs), cetuximab and panitumumab, represent an effective treatment option for patients affected by metastatic colorectal cancer (mCRC); furthermore, they are relatively devoid of system
Autor:
Alberto Luini, Mattia Intra, Marco Colleoni, Cristiano Rampinelli, Vincenzo Bagnardi, Francesco Bertolini, Giuseppe Viale, Giuseppe Cancello, Davide Pastrello, Emilia Montagna, Silvia Dellapasqua, Gino Perri, Aron Goldhirsch, Angelica Calleri, Paolo Veronesi
The aim of this study was to determine the safety and efficacy of metronomic chemotherapy combined with targeted drugs in patients with metastatic breast cancer (MBC). We included 26 untreated patients with HER2-negative (HER) MBC and poor hormone re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7027862f4de931e6f979351a3350a1f6
http://hdl.handle.net/10281/30993
http://hdl.handle.net/10281/30993
Autor:
Monica Ventura, Paola Neri, Gino Perri, Donatella Paolino, Teresa Calimeri, Alessandra Bulotta, Donato Cosco, Pierfrancesco Tassone, Massimo Fresta, Nicola Costa, Pierosandro Tagliaferri, Christian Celia
Publikováno v:
Cancer chemotherapy and pharmacology. 64(5)
Gemcitabine (GEM) is presently the standard option for the treatment of advanced pancreatic cancer (PC). We investigated the in vitro and in vivo antitumor potential of GEM-loaded PEGylated liposomes (L-GEM) as a novel agent for the treatment of PC.
Autor:
Mariamena Arbitrio, Alessandra Bulotta, Monica Ventura, Teresa Calimeri, Gino Perri, M. Propato, M. Pacicca, Pierfrancesco Tassone, Pierosandro Tagliaferri, M T Di Martino
Publikováno v:
Cancer Research. 69:3128-3128
BRCA1 plays a critical role in DNA-damage repair mechanisms elicited by cell exposure to anti-tumor agents. HCC1937 is a BRCA1-defective breast cancer cell line which discloses higher sensitivity to cisplatinum (CDDP) as compared to the BRCA1 full-le